Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
Public ClinicalTrials.gov record NCT02229851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.
Study identification
- NCT ID
- NCT02229851
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 301 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 23 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2014 (Actual)
- Primary completion
- Apr 21, 2017 (Actual)
- Completion
- May 7, 2018 (Actual)
- Last update posted
- Nov 23, 2020
2014 – 2018
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35233 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90033 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90095 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30318 | — |
| Novo Nordisk Investigational Site | Roswell | Georgia | 30076 | — |
| Novo Nordisk Investigational Site | Topeka | Kansas | 66606 | — |
| Novo Nordisk Investigational Site | Baltimore | Maryland | 21205 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02114 | — |
| Novo Nordisk Investigational Site | East Lansing | Michigan | 48824 | — |
| Novo Nordisk Investigational Site | St Louis | Missouri | 63110 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68105 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68198-4120 | — |
| Novo Nordisk Investigational Site | Las Vegas | Nevada | 89128 | — |
| Novo Nordisk Investigational Site | Reno | Nevada | 89511 | — |
| Novo Nordisk Investigational Site | New York | New York | 10032 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44195 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97239 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| Novo Nordisk Investigational Site | El Paso | Texas | 79935 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Plano | Texas | 75093 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78229 | — |
| Novo Nordisk Investigational Site | Shavano Park | Texas | 78231 | — |
| Novo Nordisk Investigational Site | Salt Lake City | Utah | 84103 | — |
| Novo Nordisk Investigational Site | Federal Way | Washington | 98003 | — |
| Novo Nordisk Investigational Site | Seattle | Washington | 98122-5789 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02229851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2020 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02229851 live on ClinicalTrials.gov.